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Abstract 
 
Diabetes mellitus (DM) represents a range of metabolic disorders characterized by hypergly-
cemia resulting from insulin deficiency or insulin resistance or both. Hyperglycemia, the pri-
mary clinical manifestation of diabetes, is strongly associated with development of the diabetic 
complications. Complications caused by hyperglycaemia involve damage to the small vessels 
such as in neuropathy, nephropathy, and retinopathy, and large blood vessels as in cardiovas-
cular diseases. It is well known established that in diabetes, long-term complications ensue 
from abnormal regulation of glucose metabolism. In fact, all manifestations of cardiovascular 
disease, coronary heart disease, stroke and peripheral vascular disease are substantially more 
common in patients with type 2 diabetes than in non-diabetic individuals. For example, pa-
tients with type 2 diabetes (T2DM) have a two- to fourfold increased risk of fatal and non-fatal 
coronary events. Diabetes can lead to microvascular and macrovascular damage through a 
number of mechanisms, each of which may worsen or accelerate the others. The present re-
view summarizes the information on the mechanisms of how vascular complications will de-
velop in type 2 diabetes and this might be useful as a direction for further research to provide 
new strategies for prevention and treatment of these complications in their early stages. 
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Introduction 
 
The term diabetes mellitus describes a metabolic disorder 
of multiple etiologies characterized by chronic hypergly-
cemia with disturbances of carbohydrate, fat, and protein 
metabolism resulting from defects in insulin secretion 
and/or insulin action. Diabetes can be classified into two 
major classes: type 1 diabetes (T1DM) and type 2 diabe-
tes (T2DM). T1DM is the classical form of diabetes and 
these subjects cannot survive without insulin treatment. 
T2DM is a group of genetically determined diseases 
which may be controlled by diet, hypoglycemic agents 
and/or exogenous insulin [1]. T2DM is mainly character-
ized by insulin resistance, but impairment in insulin secre-
tion also occurs in type 2 diabetes [2,3]. 
 
Subjects with T2DM cannot compensate for insulin resis-
tance at hyperglycemic levels by increasing insulin secre-
tion [1]. Several human monogenic forms of diabetes 
have been identified including: maturity-onset diabetes of 
the young (MODY) [4], which can be caused by muta-
tions in the glucokinase gene. MODY is characterized by 
β-cells dysfunction and young age at diagnosis, usually 
less than 25 years, leading to early-onset T2DM. In addi-
tion, other minor classes include gestational diabetes, ext-
reme insulin resistance caused by a defective insulin re-
ceptor gene, the diabetes-deafness and optic atrophy syn-
drome which is due to defects in mitochondrial genes [5], 
and latent autoimmune diabetes in adults (LADA) [6,7] 
which was introduced to define adult diabetic patients 
who initially present as type 2 diabetics but with immune 
markers of type 1 diabetes which, in a number of cases, 
progress to insulin dependency. However, LADA more 
closely resembles and shares common characteristics of 
T1DM including genetics, metabolic dysfunction, and 
autoimmune features, but LADA does not affect children 
and is classified distinctly as being separate from juvenile 
diabetes. T1DM and the minor classes of diabetes will not 
be discussed any further in this review. 
 
Type 2 diabetes mellitus 
 
Epidemiology  
 
It is well established that the most common form of dia-
betes is type 2 diabetes. The global rise in diabetes [8, 9] 
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occurs because of population growth and ageing, and be-
cause of increasing trends towards an unhealthy diet, obe-
sity, and sedentary lifestyles [10]. Type 2 diabetes repre-
sents about 85% to 95% of  the people with diabetes in 
developed countries and an even higher percentage in 
developing countries [11]. Amos et al. estimated that 
there were 124 million persons with diabetes in the world 
in 1997 and predicted this number would grow to 221 
million in 2010 [12]. Another study group estimated that 
the number of persons with diabetes was 150 million in 
2000 and this number is expected to double by 2025 [13]. 
In 2003, it was estimated that approximately 194 million 
people worldwide, or 5.1% in the age group 20-79, have 
diabetes.  
 
The largest increase in the prevalence numbers is thought 
likely to appear in India, China and other developing 
countries. This estimate is expected to increase to 6.3% in 
the adult population, by 2025. In the United States, the 
National Health and Nutrition Examination Surveys 
(NHANES) I and II showed that the prevalence of DM 
between 1976 and 1994 among American adults increased 
from 6.6% to 7.8% [14]. Although the absolute increase is 
relatively small, when the U.S. population growth during 
this period is considered, the number of patients with DM 
almost doubled from an estimated 8 million to 15.6 mil-
lion people. Similar pictures have been observed in 
Europe, in which DM affects about 8.5% of the adult 
population [15]. The European Region with 48 million 
and Western Pacific Region with 43 million currently 
have the highest number of people with diabetes. How-
ever, the prevalence rate of 3.1% for the Western Pacific 
Region is significantly lower than 7.9% in the North 
American Region and 7.8% in the European Region. By 
2025, the region with the greatest number of persons with 
diabetes is expected to change to the South-East Asian 
Region with about 82 million. The region’s prevalence of 
7.5% will however continue to be lower than that of 
North America, estimated at 9.7%, and Europe at 9.1%. 
[16].  
 
Table 2: List of countries with the highest numbers of estimated cases of diabetes for 2000 and 2030 
 
2000 2030 
 
 
Ranking 
Country 
 
People with diabetes 
(millions) 
Country 
 
People with diabetes 
(millions) 
 
1 India 31.7 India 79.4 
2 China 20.8 China 42.3 
3 U.S. 17.7 U.S. 30.3 
4 Indonesia 8.4 Indonesia 21.3 
5 Japan 6.8 Pakistan 13.9 
6 Pakistan 5.2 Brazil 11.3 
7 Russia 4.6 Bangladesh 11.1 
8 Brazil 4.6 Japan 8.9 
9 Italy 4.3 Philippines 7.8 
    10 Bangladesh 3.2 Egypt 6.7 
 
 
Gu et al. conducted a national study to investigate the 
prevalence of diabetes in 15,540 adults from 31 provinces 
in China. The authors reported that in China three out of 
four individuals with diabetes were undiagnosed and the 
prevalence of diabetes was 5.5% among the population 
aged 35  to 74 years in 2000. In  addition, the age-
standardized prevalence of diabetes of the population 
aged 35 to 74 living in urban area (7.8%) was higher than 
that of those living in rural area (5.1%) [17]. In Sweden, 
about 50,000 people are diagnosed with type 2 diabetes 
every year, with a prevalence of 4% or more [18]. Table 1 
showed the 10 countries estimated to have the highest 
numbers of people with diabetes in 2000 and 2030 [19]. 
The 40-59 age group currently has the greatest number of 
persons with diabetes. By 2025, because of the aging of 
the world’s population, there will be 146 million aged 40-
59 and 147 million aged 60 or older with diabetes.  
 
 
 
Pathogenesis and major risk factors 
 
Impaired insulin action and impaired pancreatic insulin 
secretion represent the principal pathophysiological ab-
normalities leading to increase blood glucose levels 
[20,21]. These are present to varying degrees in almost all 
patients with the common form of T2DM. Insulin resis-
tance is a common pathologic state in which target cells 
fail to respond to the physiological effects of insulin oc-
curring in peripheral organs and leading to abnormalities 
in glucose, lipid and protein metabolism [22]. When the 
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target tissue does not respond to even high levels of insu-
lin, glucose builds up in the blood resulting in high blood 
glucose or type 2 diabetes. In fact, insulin resistance is 
present in the majority of patients with impaired glucose 
tolerance or T2DM, and it is also found in up to 25 % of 
the general, apparently healthy population [23].  
 
 
 
In response to elevated blood glucose concentration due 
to insulin resistance, pancreatic β-cells need to increase 
the insulin secretion to maintain homeostasis in glucose 
levels. Finally, β-cells become unresponsive to glucose 
due to pancreatic β-cells dysfunction and eventually type 
2 diabetes develops. Although the etiology of the β-cell 
dysfunction of diabetes is incompletely understood, it is 
thought to result from both genetic and environmental 
factors [24,25]. Current study provided evidence to em-
phasis that both insulin resistance and β-cell dysfunction 
are associated processes and that β-cell dysfunction must 
be present for even minimal increases in blood glucose 
[26]. Family history, diet, and lack of physical activity are 
all major risk factors for developing T2DM. Dyslipidemia 
and high blood pressure are other risk factors that often 
appear before the clinical disease is evident [27]. Elevated 
levels of free fatty acids are also strong predictor of diabe-
tes and correlate with hepatic glucose output, a major 
cause of diabetic hyperglycemia [28], high glucose levels, 
and obesity. 
 
Type 2 diabetes and metabolic syndrome 
 
A majority of patients with T2DM have features of the so-
called metabolic syndrome, which has also been called 
“Syndrome X” [23]. The major components of the meta-
bolic syndrome include abdominal obesity, glucose intol-
erance/T2DM, dyslipidemia and hypertension [29]. The 
prevalence of the metabolic syndrome has varied mark-
edly between different studies, most likely because of the 
lack of accepted criteria for the definition of the syndrome 
[30, 31]. WHO proposed a unifying definition for the 
syndrome and chose to call it the metabolic syndrome, 
rather than the insulin resistance syndrome [32]. The main 
reason was that it was not established that insulin resis-
tance is the cause of all the components of the syndrome.  
 
Cardiovascular disease 
 
Cardiovascular disease (CVD) has for a long time been 
among the worldwide public health problem. Since 1919, 
cardiovascular disease has remained the leading cause of 
death in the United States. The direct and indirect costs of 
CVD in this country are estimated to reach $403 billion in 
2006 alone. Although CVD includes several types of vas-
cular and heart diseases, atherosclerosis is the cause of 
approximately 75% of all CVD-related deaths [33]. The 
problems associated with CVD are severe in all parts of 
the world; however, the manifestations vary between dif-
ferent countries. In China, Japan and many Africans coun-
tries for example, stroke is more common than coronary 
heart disease whereas, among Caucasian populations, 
coronary heart disease is more common. In some devel-
oped  
nations, such as the USA, Australia and Europe, where 
coronary heart disease rates were previously very high, 
mortality has fallen in recent decades [34]. However, in 
other areas such as Eastern Europe and the Middle East, 
the opposite is true. The “top ten” countries for both 
coronary and cerebrovascular disease mortality rates are 
now mainly from Eastern Europe and the former Soviet 
Union. 
 
The clinical manifestations of CVD include coronary ar-
tery disease (CAD), cerebrovascular disease, and periph-
eral vascular disease. The underlying disease mechanism 
is accelerated atherosclerosis. The atherosclerotic process 
starts from fatty streaks, consisting of intimal deposits of 
lipids and macrophages with lipid droplets (foam cells), 
gradually developing into more advanced plaques. The 
process ends up in complicated atherosclerotic lesions, 
which through a plaque rupture and thrombosis can cause 
an acute myocardial infarction [35]. 
 
Type 2 diabetes and macrovascular complica-
tions 
 
Macrovascular complications of DM are due to acceler-
ated atherosclerosis and have an important role in the in-
creased morbidity and mortality suffered by these indi-
viduals [36]. The mechanism behind the relation between 
diabetes and atherosclerosis is not fully understood. Oxi-
dative stress caused by production of reactive oxygen spe-
cies (ROS) has been proposed as the main cause underly-
ing insulin resistance, type 2 diabetes and vascular com-
plications [37]. Additionally, both impaired glucose me-
tabolism [38] and diabetic dyslipidemia [39] might con-
tribute to the atherosclerotic process. Patients with T2DM 
are more at risk to develop macrovascular disease, both at 
an earlier age and in a higher frequency as compared to 
the general non-diabetic population.  
 
The severity of cardiovascular complications in diabetes 
is demonstrated by the statistic that diabetics are 2  to 4 
times more likely to have a stroke or  die of heart disease 
than non-diabetics. Cardiovascular disease accounts for 
about 70% of all deaths in patients with diabetes [40]. It 
has been established in a more recent report that heart 
disease is the leading cause of diabetes-related deaths in 
the United States alone [41]. The presence of diabetes, in 
addition to any or all the other risk factors (such as smo-
king, hypertension, dyslipidemia, and genetic factors), 
Ahmad/ Muniandy/ Ismail 
 
                                                                                                                                                          Biomedical Research 
 
150
approximately doubles the probability of developing ma-
crovascular diseases and the available evidence suggests 
that strict diabetic control does not prevent or delay these 
complications [42]. Cardiovascular complications are of-
ten present already at the time of diagnosis of T2DM and 
subjects with impaired glucose tolerance (IGT) have an 
approximately two-fold increase in the risk of macrovas-
cular diseases [43]. Epidemiological studies have shown 
that the risk of cardiovascular mortality is two to three 
times higher in men and three to five times higher in 
women with diabetes than in non-diabetic subjects [44]. 
Ryden et al. showed that there is a steep rise in diabetes 
prevalence after the age of 50 in men and after the age of 
60 in women [45].  
 
Pathogenesis and major risk factors of diabetic 
complications  
  
 Hyperglycemia  
 
A strong consistent relationship has been postulated be-
tween hyperglycemia and the incidence and progression 
of micro- and macrovascular complications in people with 
diabetes [46]. Studies on nondiabetic subjects have ob-
served that even slightly elevated serum glucose concent-
rations increase risk for cardiovascular disease [47]. Epi-
demiological data have revealed hyperglycemia to be a 
major player in the development of the macrovascular 
complications such as CAD and stroke [41]. Prospective 
clinical studies in T2DM patients have shown an associa-
tion between level of hyperglycemia and increased risk  
for mortality due to macrovascular disease [48,49]. The  
San Antonio Heart Study demonstrated that hyperglyce 
mia is a risk factor not only in Caucasians, but also in 
other ethnic groups [50]. The data of the UK prospective 
diabetes study (UKPDS) suggest that any improvement in 
glycemic control among patients with T2DM is likely to 
reduce the risk of diabetic complications [51].  
 
Protein kinase C  
 
Protein kinase C (PKC) is a family of serine-threonine 
kinases that plays an important role in signal transduction 
mechanisms [52]. The PKC pathway is activated in diabe-
tes as a result of hyperglycemia (Fig. 1). In this pathway, 
PKC is activated by the increased amounts of diacylglyc-
erol (DAG), which are synthesized directly from glyco-
lytic intermediates such as dihydroxyacetone phosphate 
and glyceraldehyde-3-phosphate [53]. It is possible that 
also advanced glycation end products and oxidants in-
crease formation of DAG and activate PKC [54]. PKC 
appears to be activated in a range of diabetic tissues in-
cluding the retina, kidney, heart, and aorta [55]. An acti-
vation of PKC has been implicated in many processes 
relevant to diabetic complications, including regulation of 
vascular permeability and flow, increased production of 
cytokines, and increased synthesis of basement mem-
branes [56]. In diabetes microvascular complications, for 
example, PKC affects the activation of a number of 
growth factors and changes the function of vasoactive 
factors. These vasoactive factors include vasodilators 
such as nitric oxide (NO) as well as vasoconstrictors such 
as angiotensin II and endothelin-1 [57, 58]. 
 
 
 
 
Figure 1. Scheme represents protein kinase C and polyol pathways in the pathogenesis of diabetic 
complications. GAP, glyceraldehydes-3-phosphate; DAG, diacylglycerol; PKC, protein kinase C; 
AR, aldose reductase; SDH, sorbitol dehydrogenase.  
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Polyol pathway 
 
Only a small proportion of glucose is metabolized to sor-
bitol during normoglycemia, while in hyperglycemia the 
enzyme aldose reductase is activated, leading to an ac-
cumulation of intracellular sorbitol and fructose that in-
creases the flux through the polyol pathway [59]. Sorbi-
tols and other polyols accumulate intracellularily, lead-
ing to osmotic damage and swelling. Aldose reductase 
(AR) is the first and rate-limiting enzyme of the polyol 
pathway, which converts monosaccharides (e.g. glucose) 
to their polyols or sugar alcohols (e.g. sorbitol) as seen 
in Fig. 1. This enzyme is widely distributed throughout 
the body, including those tissues that are susceptible to 
chronic diabetic complications (e.g. retina, lens, cornea, 
glomerulus, nervous system and the blood vessels) [60, 
61]. In fact, alterations in sorbitol and fructose meta-
bolism are implicated as factors contributing to vascular 
complications in diabetes mellitus [60]. 
 
Advanced glycation end products  
 
Non-enzymatic glycation has recently attracted increas-
ing interest as a crucial pathophysiologic event behind 
hyperglycemia-related alterations and in the pathophysi-
ology of the development of diabetic complications. Pro-
teins and lipids exposed to aldose sugars go through re-
actions, which ultimately lead to the formation of ad-
vanced glycation end products (AGEs), a heterogeneous 
mixture of complex structures [62]. Although the series 
of reactions producing AGEs occurs at a very slow rate 
under normal circumstances, in diabetes their formation 
is accelerated to an extent related to the level and dura-
tion of hyperglycemia [63,64].  
 
The potential pathophysiological significance of AGEs 
is associated with their accumulation in plasma, cells 
and tissues and their contribution to the formation of 
cross-links, generation of reactive oxygen intermediates, 
and interactions with particular receptors on cellular sur-
faces [65]. It has been reported by Cipollone and co-
workers that advanced glycation end products might 
contribute to the atherosclerotic process seen in T2DM 
[66]. More    details about AGEs and the well-
characterized form of AGEs; Nε-(carboxymethyl)lysine 
were discussed by     Ahmed et al. [67]. 
 
Genetic factors 
 
Despite the crucial role of hyperglycemia on diabetic 
complications, other factors such as hypertension, obe-
sity, and hyperlipidemia undoubtedly contribute. There 
are patients with longstanding hyperglycemia without 
complications and patients with short duration of dis-
ease who seem to be very prone to complications. Ge-
netic factors are obviously important as prevalence is af-
fected by the background population. Studies using sev-
eral techniques including twin studies and diabetic ani-
mals have revealed definitive genetic predispositions to-
the development of diabetes [68,69] and these predispo-
sitions might be dependent on environmental stimulants.  
 
An important variability in the incidence of diabetes-
derived chronic complications exists, which may indi-
cate the existence of a predetermined genetic susceptibi-
lity in its onset. The association between obesity and 
T2DM is well known and studies have started to focus 
on the biological basis for this link. In fact, about 60-
90% of T2DM patients are overweight or obese thereby 
providing ample support for the term “diabesity” used to 
describe obesity-related T2DM [70,71]. A strong sup-
port for the presence of an underlying genetic predispo-
sition in those obese individuals who progress to T2DM 
has been provided by fact that while most T2DM pa-
tients are obese, most obese patients not necessary to 
have overt T2DM.   
 
Type 2 diabetes and microvascular complica-
tions 
 
Diabetic retinopathy  
 
Diabetes results in characteristic lesions in the retinal 
blood vessels. Diabetic retinopathy is still the most com-
mon cause of acquired blindness in the Western world 
[72]. Its prevalence increases most steeply between 5 to 
15 years of diabetes duration, being about 60% after 20 
years in the European population. This can result in for-
mation of microaneurysms (minimal retinopathy), haem-
orrhages and increased leakage, causing retinal edema 
and lipid exudates (background retinopathy). When 
pathological development of new vessels in the retina or 
abnormal blood vessels and fibrous tissue (i.e. neovascu-
larisation) occurs, the retinopathy is classified as prolif-
erative retinopathy [73]. The formation of fibrous tissue 
may eventually cause retinal detachment and severe vis-
ual impairment [74]. Also, an excess of glucose activates 
the polyol pathway, which causes accumulation of sorbi-
tol in the lens and is accompanied by cataracts [75]. The 
etiology of retinopathy includes hyperglycemia-
associated biochemical, anatomical, and functional 
changes.  
 
Diabetic nephropathy 
 
Diabetic nephropathy is estimated to develop in one 
third of both main types of diabetes [76]. Nephropathy is 
characterized by glomerular basement membrane thick-
ening and arteriosclerosis of small arterioles. The hall-
mark of renal damage in diabetes is increased excretion 
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of albumin in the urine. The natural history of diabetic 
nephropathy has been viewed as a descending path from 
normoalbuminuria to microalbuminuria, clinically overt 
diabetic nephropathy; i.e macroalbuminuria, and eventu-
ally to end-stage renal disease. The term microalbu-
miuria; i.e. incipient diabetic nephropathy, has been de-
fined as urine albumin excretion rate 20-200 μg/min in a 
timed overnight or 30-300mg/24h urine collection [77] 
as determined by sensitive laboratory measurements. 
Urine albumin excretion rate exceeding these values is 
called       macroalbuminuria and considered a sign of 
manifest diabetic nephropathy. It has been estimated that 
approximately half the patients with microalbuminuria 
will progress to overt nephropathy [78]. In fact, most of 
the hemodialysis patients and the patients receiving renal 
transplants have diabetes [79].  
 
Diabetic neuropathy 
The term diabetic neuropathy includes either a clinical or 
subclinical disorder without any additional causes of pe-
ripheral neuropathy other than diabetes. In fact, damage 
to the microvasculature in peripheral nerves is now be-
coming recognized as a major pathogenic factor in dia-
betic neuropathy [80]. It may affect both sensory and 
autonomic nerves, but distal symmetric polyneuropathy 
is probably the most common consequence which, to-
gether with peripheral vascular disease, is an important 
etiologic factor for foot ulcerations and lower limb am-
putations. Autonomic dysfunction is common in people 
with diabetes, but is only clinically apparent in a small 
percentage. 
 
Diabetic neuropathy is encountered in about half of all 
people with diabetes either as a polyneuropathy or 
mononeuropathy [81] especially in patients over 60 
years age with T2DM [82]. Although exact prevalence 
depends on the diagnostic criteria used to identify neu-
ropathy, most studies suggest that 50% of patients with a 
20-years history of either type 1 or type 2 diabetes have 
neuropathy [83,84]. Around 10% of these cases of neu-
ropathy are associated with abnormal sensations and 
pain [85]. The incidence of neuropathy increases with 
duration of diabetes and is accelerated by poor control 
[86]. Additionally, the death rate is as high as 50% at 
three years after diagnosis of overt autonomic neuropa-
thy [82]. 
 
How big is the problem? 
 
Normally properly treated diabetes is symptomless, but 
continuing hyperglycemia seen in type 2 diabetes can 
give rise to chronic complications [87] including reti-
nopathy, neuropathy and nephropathy [88], and macro-
vascular complications [89]. A common denominator for 
all microvascular and macrovascular complications is 
extensive vascular damage. Both of these conditions are 
life threatening and may result in an altered mental state, 
loss of consciousness, and possibly death; therefore 
prompt medical attention is necessary to avoid adverse 
outcomes. Microvascular complications comprise 
changes in the small blood vessels of the eye that result 
in diabetic retinopathy, in the peripheral nerves, causing 
neuropathy, and finally in the kidney, causing diabetic 
nephropathy. As a result, diabetes is the most common 
cause of blindness, end-stage renal disease [90], and 
limb amputation [91]. 
 
In macrovascular complications, accelerated atheroscle-
rosis results in cardiovascular disease (CVD) such as 
coronary heart disease (CHD) and acute myocardial in-
farction (AMI). Through its effects on cardiovascular 
disease (70-80% of people with diabetes die of cardio-
vascular disease), diabetes is also now one of the leading 
causes of death. While the pathogenesis of these compli-
cations has been extensively studied for the past 50 
years, no single etiology exists to explain all types of 
complications. Instead, multiple etiologies exist that are 
specific to each. The cost to care for patients with DM in 
the U.S. was approximately $132 billion. Of those costs, 
$40 billion was indirect medical expenses (disability, 
work loss, and premature deaths), and $92 billion dollars 
was direct medical expenses (those attributable to the 
disease itself, i.e. microvascular and macrovascular 
complications) [92]. In fact, approximately 25% of the 
total Medicare budget is used for the treatment of DM 
and its complications [93, 94].  
 
In Africa, the burden of diabetes cost is huge and de-
pending upon the individual and the family. It has been 
established that 50% of diabetes care is paid by the pa-
tients, 44% by the family, 2% by the employer, 2% 
charities and others, and only 2% by the government 
[95]. Therefore, recommendations founded on the results 
of Guerci et al. study showing benefits of intensive gly-
cemic control [96]. Thus, development of tools and 
models for diabetes health care could potentially result 
in a substantial decrease in diabetes-associated vascular 
complications.   
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